Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
Bortezomib and Lenalidomide have been shown to be effective in the control of multiple myeloma (MM) progression. We have investigated their role in the in vitro expression of Osterix by primary osteoblast cultures from MM patients and found that Osterix RNA was constitutively down-regulated in these cells. Treatment of osteoblasts with Bortezomib resulted in an increase of Osterix RNA and in enhanced activity of both BMP-2 and Runx2. Instead, Lenalidomide was unable to modify Osterix transcription. These findings provide additional evidence suggesting that, at least in vitro, Bortezomib promotes the osteoblast maturation whereas Lenalidomide is ineffective.
De Matteo
Monica
M
DIMO, Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza Giulio Cesare 11, 70124, Bari, Italy.
Brunetti
Anna Elisabetta
AE
Maiorano
Eugenio
E
Cafforio
Paola
P
Dammacco
Franco
F
Silvestris
Franco
F
D000970:Antineoplastic Agents / Q000494:pharmacology; D055396:Bone Morphogenetic Protein 2 / Q000187:drug effects; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D016022:Case-Control Studies; D002454:Cell Differentiation; D050659:Core Binding Factor Alpha 1 Subunit / Q000187:drug effects; D015536:Down-Regulation / Q000187:drug effects*; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D011719:Pyrazines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000187:drug effects; D000076182:Sp7 Transcription Factor; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology; D014157:Transcription Factors / Q000235:genetics*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D001897:Boronic Acids; D050659:Core Binding Factor Alpha 1 Subunit; D011719:Pyrazines; D012333:RNA, Messenger; C493709:RUNX2 protein, human; D000076182:Sp7 Transcription Factor; C478163:SP7 protein, human; D014157:Transcription Factors; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide